Objective Prevalence rates of anxiety disorders in Parkinson's disease (PD) vary widely,
ranging from 6% up to 55%. The aim of this systematic review was to calculate the average …

Advancing conventional open‐loop DBS as a therapy for PD is crucial for overcoming important
issues such as the delicate balance between beneficial and adverse effects and limited …

Background Cognitive impairment is a common non-motor symptom in Parkinson's disease.
So far, the underlying pathophysiology remains unclear. Several alterations in functional …

… The acute-phase patient sera with GB4, GB15, and GB24 did not contain antiganglioside
antibodies (2; ML Kuijf, unpublished data), suggesting a pathogenic mechanism other than …

… 70 mT/m and a 200 T/m/s slew rate using a 32-element head array coil (Nova Medical, Inc,
Burlington, MA, USA), while taking their usual antiparkinsonian medication. Dielectric pads (…

We used various genotyping methods to identify bacterial genetic markers for development
of arthritic symptoms following Campylobacter enteritis. We genotyped a collection of …

Background Our understanding of the etiology, pathophysiology, phenotypic diversity, and
progression of Parkinson’s disease has stagnated. Consequently, patients do not receive the …

In Guillain-Barré syndrome (GBS), ganglioside mimicry of Campylobacter jejuni lipo-oligosaccharide
(LOS) drives the production of cross-reactive Abs to peripheral nerve gangliosides. …

… serum antibodies to myelin-associated glycoprotein (MAG) by Western blot (WB) is a valuable
assay to diagnose a distinct type of demyelinating polyneuropathy with immunoglobulin M …

The Inflammatory Neuropathy and Treatment (INCAT) group developed a standardized
ELISA method for the detection of serum anti-GM1 antibodies. The diagnostic value of anti-GM1 …